Metabolic (formerly GluCare.Health) has launched a three-month prospective observational study to evaluate the effectiveness of the Dexcom G7 continuous glucose monitoring (CGM) system in improving glycaemic control among patients with type 2 diabetes in the UAE.

The study will assess changes in HbA1c and other key glucose monitoring metrics within Metabolic’s multidisciplinary, technology-enabled care model. All participants will receive Dexcom G7 sensors free of charge, ensuring equal access throughout the study.

Click here to join our WhatsApp channel here

Dr. Ihsan Almarzooqi, Co-Founder and Managing Director of Metabolic, commented: “Continuous glucose monitoring is one of the most powerful tools available for understanding a patient’s metabolic reality in real time. Our clinical team will gain a depth of insight that goes far beyond what standard clinic visits can provide. This study will give us robust evidence for the role of CGM within a structured T2D care programme, and we expect the findings to meaningfully inform how we deploy this technology at scale.”

Also read: WHO Warns Global Cancer Cases Could Nearly Double by 2050

The research aims to generate real-world evidence on the use of CGM in structured type 2 diabetes care, particularly in the Gulf region where diabetes prevalence remains high. Metabolic said the findings could help guide wider adoption of CGM technology to improve long-term diabetes management and patient outcomes.